I note Prana's results from their Phase Two study are out...

I note Prana's results from their Phase Two study are out tonight. Results are encouraging and we will know how encouraging when the Nasdaq fires up tonight. Not too sure myself.

It led me to thinking about how much better our Uniqure product might be!

Benitec have access to their AAV technology which is all well and good but I am a bit mystified as to why BLT have said AAV2 (as opposed to aav8) has implications for the HCB work being done. If the aav8 vector works in HCV then it would be a fair bet they would use it for Hep B.

I am thinking that there may in fact be newer and better vectors being worked on by Uniqure.

Benitec NOT having a lab is likely going to prove to be a good thing at this early stage IMO. The reason being is that there are so many advances coming through in delivery that by going down only one path in our own lab could be an issue. Why not let some of the dust settle, get the ddRNAi proven and then start up our own labs.